Binding Site
Sector/industry
Clinical laboratory diagnostics
Binding Site is a specialised
diagnostics company producing protein tests for diagnosis of
certain blood cancer diseases as well as immunological disorders.
With extensive expertise in antibody specificity technology,
Binding Site gives clinicians and laboratory staff the tools to
significantly improve diagnosis and management of patients across a
range of cancers and immune system disorders.
The UK head office houses all product
development, manufacturing, global distribution and marketing.
Worldwide customer support is also provided by a further 7 offices
in the US and Europe.
Binding Site was acquired by Nordic Capital Fund VII in
2011
Management:
- Charles de Rohan, CEO
- Mark Culwick, CFO
Board of Directors:
- Kristoffer Melinder, Chairman
- Jonas Agnblad
- Jo Bradwell
- Hugh Carr-Smith
- Paul Hökfelt
- Javed Kahn
- Heino von Prondzynski
- Charles de Rohan
- Tommi Unkuri
Key Information:
Revenues 2012 *:
EUR 70 million
Employees:
580
Ownership:
Nordic Capital Fund VII, controlling shareholding
Date of investment:
2011
Head office:
Birmingham, UK
* Normalized pro-forma adjusted for FX effects
